Discounted Cash Flow
Emergent Biosolutions Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $488.8m | $51.8m | $-22.8m | 10.6% | $1.29 |
| 2017 | $560.9m (14.7%) | $82.6m (59.5%) | $153.3m (773.3%) | 14.7% (39.0%) | $1.98 (53.5%) |
| 2018 | $782.4m (39.5%) | $62.7m (-24.1%) | $-30.3m (-119.8%) | 8.0% (-45.6%) | $1.25 (-36.9%) |
| 2019 | $1.1b (41.4%) | $54.5m (-13.1%) | $101.1m (433.7%) | 4.9% (-38.5%) | $1.06 (-15.2%) |
| 2020 | $1.6b (40.6%) | $305.1m (459.8%) | $395.0m (290.7%) | 19.6% (298.1%) | $5.79 (446.2%) |
| 2021 | $1.8b (15.3%) | $230.9m (-24.3%) | $96.1m (-75.7%) | 12.9% (-34.3%) | $4.32 (-25.4%) |
| 2022 | $1.1b (-37.7%) | $-211.6m (-191.6%) | $-149.9m (-256.0%) | -18.9% (-247.0%) | $-4.22 (-197.7%) |
| 2023 | $1.0b (-6.1%) | $-760.5m (-259.4%) | $-257.9m (-72.0%) | -72.5% (-282.8%) | $-14.85 (-251.9%) |
| 2024 | $1.0b (-0.5%) | $-190.6m (74.9%) | $35.8m (113.9%) | -18.3% (74.8%) | $-3.60 (75.8%) |
| 2025 | $742.9m (-28.8%) | $52.6m (127.6%) | $156.8m (338.0%) | 7.1% (138.8%) | $0.98 (127.2%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.